Loading patent…
AssigneesNorges Miljo-OG Biovitenskapelige Universitet (NMBU), Sykehuset Ostfold HF, University of Copenhagen
InventorsTOR LEA, CHARLOTTE KLEIVELAND, KARSTEN KRISTIANSEN, BENJAMIN ANDERSCHOU HOLBECH JENSEN
Estimating the term…
The invention provides a method for the treatment or prevention of GI tract dysbiosis in a subject, said method comprising administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. The invention further provides a method for the treatment or prevention of a disease or condition selected from small intestine bacterial overgrowth (SIBO), small intestine fungal overgrowth syndrome (SIFO), GI tract cancers, breast cancer, neurological disorders, malnutrition, chronic fatigue syndrome, autism, cardiovascular diseases and GI tract infections in a subject with GI tract dysbiosis, said method comprising administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. A non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus for use in said methods is further provided.
(canceled)
(canceled)
A method for treatment or prevention of GI tract dysbiosis in a subject, said method comprising administering an effective amount of a non-viable Methylococcus capsulatus or a lysate ofMethylococcus capsulatus to said subject.
A method for the treatment or prevention of a disease or condition selected from small intestine bacterial overgrowth (SIBO), small intestine fungal overgrowth syndrome (SIFO), GI tract cancers, breast cancer, neurological disorders, psychiatric disorders, malnutrition, chronic fatigue syndrome, autism, and cardiovascular diseases in a subject with GI tract dysbiosis, said method comprising administering an effective amount of a non-viable Methylococcus capsulatus or a lysate ofMethylococcus capsulatus to said subject.
(canceled)
Dependencies are inferred from the claim text.